… down 1.42%. The FBT ($45.12) First Trust Arca Biotechnology Index Fund is up 38% YTD riding some big winners like Amylin ( AMLN ) Regeneron ( REGN ) and Vertex ( VRTX ). Recently Benziga published an article on biotech ETF's reiterating the underlying …
… March 28 market cap to buyout rumors, biopharma Amylin Pharmaceuticals ( AMLN ) continues to be stubbornly silent on the question ..... ostensibly finding out more about what's going on at Amylin from Bloomberg than they are from their own management …
Amylin ( AMLN ) has apparently attracted interest from potential suitors including Pfizer ( PFE ), AstraZeneca ( AZN ), Bristol-Myers ( BMY …
… first period since the drug's January 2010 launch with a sequential decline in revenue. First quarter saw the approval of Amylin 's AMLN rival GLP-1 drug Bydureon (which requires only once-weekly dosing compared with Victoza's once-daily requirement …
… management stays silent. Currently, Amylin Pharmaceuticals ( AMLN ) is caught up in just such a drama ..... that can reveal what is happening at Amylin . Since Bloomberg reported on March 28 that Amylin had rejected a takeover offer from …
Amylin Pharmaceuticals ( AMLN ) Q1 2012 Earnings Call April 26, 2012 8:30 am ET Executives Christine Everett-Zedelmayer - Daniel M. Bradbury - Chief Executive …
Amylin AMLN saw stagnant sales and its net loss widen during first quarter ..... keeping our fair value estimate in place, which reflects Amylin 's value on a stand-alone basis. Amylin reported net product sales of $150.6 million in first …
… albiglutide could also hit the market within the next few years as a more convenient alternative to Novo Nordisk's NVO and Amylin 's AMLN competing diabetes products. Human Genome stands to receive royalties on worldwide sales of both products, should they become …
… at least somewhat involved in the race to buy Amylin Pharmaceuticals ( AMLN ) . Amylin is best known for its diabetes drugs, Bydureon ..... BMY ) made an unsolicited offer to purchase Amylin that was subsequently rejected by the company …
(Reuters) - Shares of Amylin Pharmaceuticals Inc rose 12 percent in premarket trade following a Reuters report that the drug maker is seeking buyers after it spurned a $3.5 billion buyout offer from...